0.000
0.00 (0.00%)
| Harga / Jualan (P/S) | 264.36 |
| Harga / Buku (P/B) | 36.17 |
| Margin Operasi (TTM) | -20,588.95% |
| EPS Cair (TTM) | -42.65 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 194.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 349.84% |
| Nisbah Semasa (MRQ) | 0.340 |
| Aliran Tunai Operasi (OCF TTM) | -24.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -15.22 M |
| Pulangan Atas Aset (ROA TTM) | -117.74% |
| Pulangan Atas Ekuiti (ROE TTM) | -388.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Eyenovia, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | -0.67 |
|
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.42% |
| % Dimiliki oleh Institusi | 13.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nations Financial Group Inc, /Ia/ /Adv | 31 Dec 2024 | 1,125 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |